SecBot SecBot

JAGX drug pipeline

Jaguar Health, Inc. · 2 rated drugs
$0.2270
−30.6% 1-day · Nov 20
Next catalyst
Dec 21, 2026
Canalevia PDUFA date · in 29 days
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Dec 21, 202629d
    Canalevia
    PDUFA date · diarrhea in dogs

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready FDA-approved and commercially launched in the U.S. as of October 2024.

Gelclair Gelclair (no separate generic/INN name identified; it is a branded formulation) Updated Nov 11

What to watch

Gelclair is already approved and launched, so the main thing to watch is whether Jaguar's commercial efforts gain traction in the oral mucositis market. The company has shifted strategic focus to rare-disease crofelemer programs (MVID NDA filing targeted mid-2027) and out-licensed its core Mytesi/Canalevia products to Future Pak in January 2026. Gelclair appears to be a smaller part of the portfolio now. The near-term binary catalyst for JAGX is the December 21, 2026 PDUFA for Canalevia (veterinary CID), not Gelclair.

Bull case
  • Gelclair addresses a large addressable market: oral mucositis affects up to 40% of chemotherapy patients and 90% of head and neck cancer patients undergoing radiotherapy, per the National Comprehensive Cancer Network.
  • The product is already FDA-approved and generating prescription revenue with no further clinical development risk or regulatory binary ahead.
  • Jaguar in-licensed Gelclair through a 5-year exclusive U.S. agreement, providing a commercial foothold in cancer supportive care with an established product.
Bear case
  • Gelclair is a small part of Jaguar's portfolio; the company has publicly shifted focus to rare-disease crofelemer programs and out-licensed its core products, suggesting Gelclair is not a strategic priority.
  • Jaguar Health is a micro-cap stock (~$7M market cap) with heavy dilution: recent warrant repricing to $1.00, ELOC floor price reduced to $1.10, and a reverse stock split authorized up to 1:150.
  • Minimal institutional interest: only 3 tracked 13F holders as of Q2 2026, with combined holdings of roughly $12,000.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approved December 2012).

Mytesi crofelemer Updated Nov 16

What to watch

Mytesi itself has no upcoming binary catalyst; it is a mature, declining product whose commercial risk has been transferred to Future Pak. The next major JAGX catalyst is the December 21, 2026 PDUFA date for Canalevia (crofelemer for chemotherapy-induced diarrhea in dogs), which is a separate drug. For Mytesi specifically, watch for any Future Pak-driven commercial initiatives or potential label expansion, but none are currently scheduled.

Bull case
  • Mytesi is the only FDA-approved prescription drug specifically for noninfectious diarrhea in HIV/AIDS patients, giving it a unique niche with no direct approved competitors.
  • The January 2026 out-license to Future Pak for $16M upfront (plus milestones) provides non-dilutive capital and eliminates Jaguar's sales and marketing costs (reduced >99% per Q2 2026), improving the company's cost structure.
  • The FDA granted fee waivers for Mytesi for fiscal 2027 under the Prescription Drug User Fee Act, reducing regulatory cost burden.
Bear case
  • Mytesi prescription volumes have been declining: down 5.8% sequentially and 12.2% year-over-year in Q4 2025, signaling ongoing weakness in core HIV-related sales.
  • The HIV-associated diarrhea market is a narrow niche, and the drug faces competition from OTC antidiarrheals and improved HIV antiretroviral regimens that cause fewer GI side effects.
  • Jaguar has effectively exited direct commercialization of Mytesi via the Future Pak license, meaning future revenue is limited to license fees and royalties rather than direct product sales growth.

Other drugs in filings and trials

no drug report yet
  • Canalevia Next: PDUFA date · Dec 21, 2026